Intestinal Bifidobacterium species (Bifidobacterium)

Intestinal Bifidobacterium species are Gram-positive, anaerobic, branched rod-shaped bacteria that represent one of the most significant genera within the human gut microbiota, particularly dominant in infants. They play a crucial role in host health by fermenting complex carbohydrates that are otherwise indigestible by human enzymes, producing short-chain fatty acids like acetate that support metabolic and colonic health. Beyond digestion, Bifidobacteria are vital for the maturation of the immune system and the maintenance of the mucosal barrier, preventing the translocation of pathogens and pro-inflammatory endotoxins. In clinical contexts, a reduction in Bifidobacterium abundance is frequently associated with various pathologies, including inflammatory bowel disease, obesity, and allergic disorders. Consequently, they are primary targets for microbiome-modulating therapies, including prebiotics, probiotics, and synbiotics, aimed at restoring microbial homeostasis and improving systemic health outcomes.

Other names

BifidobacteriaBifidobacterium genusLactic acid bacteria (informal)Probiotic Bifidobacteria

Bifidobacterium species act as therapeutic targets through modulation by prebiotics (which selectively stimulate their growth) or as live biotherapeutic products (probiotics). They exert effects by fermenting dietary fibers into acetate and lactate, which lowers intestinal pH and inhibits pathogens. They also interact with host immune cells via Toll-like receptors (TLRs) to promote regulatory T-cell (Treg) differentiation and enhance intestinal epithelial barrier function through the upregulation of tight junction proteins.